Carmelo Rodolico

Prof. Carmelo Rodolico

Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2011 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
JSJan Senderek
Jan Senderek
JMJuliane S. Müller
Juliane S. Müller
MDMarina Dusl
Marina Dusl
TSTim M. Strom
Tim M. Strom
VGVelina Guergueltcheva
Velina Guergueltcheva
HLHanns Lochmüller
Hanns Lochmüller

9 November 2007 in Human Mutation
Verified
Journal Article
Closed access
PDF file
MGMichela Guglieri
Michela Guglieri
FMFrancesca Magri
Francesca Magri
MDMaria Grazia D'Angelo
Maria Grazia D'Angelo
APAlessandro Prelle
Alessandro Prelle
LMLucia Morandi
Lucia Morandi
GCGiacomo P. Comi
Giacomo P. Comi
Limb girdle muscular dystrophies (LGMD) are characterized by genetic and clinical heterogeneity: seven autosomal dominant and 12 autosomal recessive loci have so far been identified. Aims of this study were to evaluate the relative proportion of the different types of LGMD in 181 predominantly Italian LGMD patients (representing 155 independent families), to describe the clinical pattern of the different forms, and to identify possible correlations between genotype, phenotype, and protein expression levels, as prognostic factors. Based on protein data, the majority of probands (n=72) presented calpain‐3 deficiency; other defects were as follows: dysferlin (n=31), sarcoglycans (n=32), α‐dystroglycan (n=4), and caveolin‐3 (n=2). Genetic analysis identified 111 different mutations, including 47 novel ones. LGMD relative frequency was as follows: LGMD1C (caveolin‐3) 1.3%; LGMD2A (calpain‐3) 28.4%; LGMD2B (dysferlin) 18.7%; LGMD2C (γ‐sarcoglycan) 4.5%; LGMD2D (α‐sarcoglycan) 8.4%; LGMD2E (β‐sarcoglycan) 4.5%; LGMD2F (δ‐sarcoglycan) 0.7%; LGMD2I (Fukutin‐related protein) 6.4%; and undetermined 27.1%. Compared to Northern European populations, Italian patients are less likely to be affected with LGMD2I. The order of decreasing clinical severity was: sarcoglycanopathy, calpainopathy, dysferlinopathy, and caveolinopathy. LGMD2I patients showed both infantile noncongenital and mild late‐onset presentations. Age at disease onset correlated with variability of genotype and protein levels in LGMD2B. Truncating mutations determined earlier onset than missense substitutions (20±5.1 years vs. 36.7±11.1 years; P=0.0037). Similarly, dysferlin absence was associated with an earlier onset when compared to partial deficiency (20.2±standard deviation [SD] 5.2 years vs. 28.4±SD 11.2 years; P=0.014). Hum Mutat 29(2), 258–266, 2008.

18 May 2010 in Muscle & Nerve
Verified
Journal Article
Closed access
PDF file
CLCostanza Lamperti
Costanza Lamperti
GFGreta Fabbri
Greta Fabbri
LVLiliana Vercelli
Liliana Vercelli
RDRoberto D‘Amico
Roberto D‘Amico
RFRoberto Frusciante
Roberto Frusciante
RTRossella Tupler
Rossella Tupler

7 May 2016 in Reviews in Endocrine and Metabolic Disorders
Verified
Journal Article
Closed access
ASAlessandro Sindoni
Alessandro Sindoni
Carmelo RodolicoCarmelo Rodolico
Carmelo Rodolico
MPMaria Angela Pappalardo
Maria Angela Pappalardo
SPSimona Portaro
Simona Portaro
SBSalvatore Benvenga
Salvatore Benvenga

1 September 2019 in The Lancet Neurology
Verified
Journal Article
Closed access
MHMichael G Hanna
Michael G Hanna
UBUmesh A Badrising
Umesh A Badrising
OBOlivier Benveniste
Olivier Benveniste
TLThomas E Lloyd
Thomas E Lloyd
MNMerrilee Needham
Merrilee Needham
AAAnthony A Amato
Anthony A Amato

1 April 2012 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
ISIsabella Scionti
Isabella Scionti
FGFrancesca Greco
Francesca Greco
GRGiulia Ricci
Giulia Ricci
MGMonica Govi
Monica Govi
PAPatricia Arashiro
Patricia Arashiro
RTRossella Tupler
Rossella Tupler